Recent Advances on Interaction Targets for Anticancer Activity of Caffeine

doi:10.21127/yaoyimr20200020

Medicine Research ›› 2021, Vol. 5 ›› Issue (1): 200020-200020.DOI: 10.21127/yaoyimr20200020

所属专题： Anticancer Agents

• • 下一篇

Recent Advances on Interaction Targets for Anticancer Activity of Caffeine

Titi Liu,^a,b Chengting Zi,^a,b Xuanjun Wang,^a,b,c Jun Sheng,^*,a,cand Huanhuan Xu^*,a,b

^aKey Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, Yunnan 650201, China
^bCollege of Science, Yunnan Agricultural University, Kunming, Yunnan 650201, China
^cState Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Kunming, Yunnan 650201, China

收稿日期:2020-12-27 修回日期:2021-01-09 出版日期:2021-01-20 发布日期:2021-01-20
通讯作者: Email: shengj@ynau.edu.cn (J. S.), xuhuan1017@163.com (H. X.)
基金资助:

Recent Advances on Interaction Targets for Anticancer Activity of Caffeine

Titi Liu,^a,b Chengting Zi,^a,b Xuanjun Wang,^a,b,c Jun Sheng,^*,a,cand Huanhuan Xu^*,a,b

^aKey Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, Yunnan 650201, China
^bCollege of Science, Yunnan Agricultural University, Kunming, Yunnan 650201, China
^cState Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Kunming, Yunnan 650201, China

Received:2020-12-27 Revised:2021-01-09 Online:2021-01-20 Published:2021-01-20
Contact: Email: shengj@ynau.edu.cn (J. S.), xuhuan1017@163.com (H. X.)
Supported by:

摘要/Abstract

摘要： Caffeine (1,3,7-trimethylxanthine) is the most frequently ingested neuroactive drug in the world and has enigmatic effects on tumor cells. Convincing evidence from in vitro, animal and human studies suggests that caffeine can inhibit cancer development and progression. Caffeine can easily pass through biological mem-branes and cross the blood-brain barrier, and it is thereby possible to bind to extracellular or intracellular molecules to exert its functions. This review mainly focuses on recent advances in the direct interaction targets of caffeine in the inhibition of malignancies and will hopefully provide valuable insights into the clinical application of caffeine to the treatment of cancers.

关键词: caffeine, interaction target, adenosine receptor, G6PDH, SIRT3

Abstract: Caffeine (1,3,7-trimethylxanthine) is the most frequently ingested neuroactive drug in the world and has enigmatic effects on tumor cells. Convincing evidence from in vitro, animal and human studies suggests that caffeine can inhibit cancer development and progression. Caffeine can easily pass through biological mem-branes and cross the blood-brain barrier, and it is thereby possible to bind to extracellular or intracellular molecules to exert its functions. This review mainly focuses on recent advances in the direct interaction targets of caffeine in the inhibition of malignancies and will hopefully provide valuable insights into the clinical application of caffeine to the treatment of cancers.

Key words: caffeine, interaction target, adenosine receptor, G6PDH, SIRT3

中图分类号:

Titi Liu, Chengting Zi, Xuanjun Wang, Jun Sheng, and Huanhuan Xu. Recent Advances on Interaction Targets for Anticancer Activity of Caffeine[J]. Medicine Research, 2021, 5(1): 200020-200020.

参考文献

[1] Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2020. CA-Cancer J. Clin. 2020, 70, 7–30.
[2] Parikh, P. K.; Ghate, M. D. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur. J. Med. Chem. 2018, 143, 1103–1138.
[3] Chen, Y.; Zhang, K.; Li, Y.; Guo, R.; Zhong, G.; He, Q. Oestrogen- related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1. J. Cell. Mol. Med. 2019, 23, 2115–2124.
[4] Maloney, S. M.; Hoover, C. A.; Morejon-Lasso, L. V.; Prosperi, J. R. Mechanisms of Taxane Resistance. Cancers 2020, 12, 3323.
[5] Zou, H.; Li, Y.; Liu, X.; Wu, Z.; Li J.; Ma, Z. Roles of plant-derived bioactive compounds and related microRNAs in cancer therapy. Phytother. Res. 2020, DOI: 10.1002/ptr.6883.
[6] Tej, G.; Nayak, P. K. Mechanistic considerations in chemotherapeutic activity of caffeine. Biomed. Pharmacother. 2018, 105, 312–319.
[7] Mackintosh, C.; Yuan, C.; Ou, F. S.; Zhang, S.; Niedzwiecki, D.; Chang, I. W.; O'Neil, B. H.; Mullen, B. C.; Lenz, H. J.; Blanke, C. D.; Venook, A. P.; Mayer, R. J.; Fuchs, C. S.; Innocenti, F.; Nixon, A. B.; Goldberg, R. M.; O'Reilly, E. M.; Meyerhardt, J. A.; Ng, K. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020, 6, 1713–1721.
[8] Gapstur, S. M.; Gaudet, M. M.; Wang, Y.; Hodge, R. A.; Um, C. Y.; Hartman, T. J.; McCullough, M. L. Coffee Consumption and Invasive Breast Cancer Incidence among Postmenopausal Women in the Cancer Prevention Study-II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 2020, 29, 2383–2386.
[9] Um, C. Y.; McCullough, M. L.; Guinter, M. A.; Campbell, P. T.; Jacobs, E. J.; Gapstur, S. M. Coffee consumption and risk of colorectal cancer in the Cancer Prevention Study-II Nutrition Cohort. Cancer Epidemiol. 2020, 67, 101730.
[10] Tamura, T.; Wada, K.; Konishi, K.; Goto, Y.; Mizuta, F.; Koda, S.; Hori, A.; Tanabashi, S.; Matsushita, S.; Tokimitsu, N.; Nagata, C. Coffee, Green Tea, and Caffeine Intake and Liver Cancer Risk: A Prospective Cohort Study. Nutr. Cancer. 2018, 70, 1210–1216.
[11] Cui, W. Q.; Wang, S. T.; Pan, D.; Chang, B.; Sang, L. X. Caffeine and its main targets of colorectal cancer. World J. Gastrointest. Oncol. 2020, 12, 149–172.
[12] Edling, C. E.; Selvaggi, F.; Ghonaim, R.; Maffucci, T.; Falasca, M. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol. Ther. 2014, 15, 524–532.
[13] Okano, J.; Nagahara, T.; Matsumoto K.; Murawaki, Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin. Pharmacol. Toxicol. 2008, 102, 543–551.
[14] Cheng, Y. C.; Ding, Y. M.; Hueng, D. Y.; Chen, J. Y.; Chen, Y. Caffeine suppresses the progression of human glioblastoma via cathepsin B and MAPK signaling pathway. J. Nutr. Biochem. 2016, 33, 63–72.
[15] Xu, H.; Hu, L.; Liu, T.; Chen, F.; Li, J.; Xu, J.; Jiang, L.; Xiang, Z.; Wang, X.; Sheng, J. Caffeine Targets G6PDH to Disrupt Redox Homeostasis and Inhibit Renal Cell Carcinoma Proliferation. Front. Cell. Dev. Biol. 2020, 8, 556162.
[16] Huang, Y. W.; Xu, H. H.; Wang, S. M.; Zhao, Y.; Huang, Y. M.; Li, R. B.; Wang, X. J.; Hao, S. M.; Sheng, J. Absorption of caffeine in fermented Pu-er tea is inhibited in mice. Food Funct. 2014, 5, 1520–1528.
[17] Xu, H.; Gan, C.; Gao, Z.; Huang, Y.; Wu, S.; Zhang, D.; Wang, X.; Sheng, J. Caffeine Targets SIRT3 to Enhance SOD2 Activity in Mitochondria. Front. Cell. Dev. Biol. 2020, 8, 822.
[18] Judelson, D. A.; Preston, A. G.; Miller, D. L.; Munoz, C. X.; Kellogg, M. D.; Lieberman, H. R. Effects of theobromine and caffeine on mood and vigilance. J. Clin. Psychopharmacol. 2013, 33, 499–506.
[19] Jacobson, K. A.; Gao, Z. G.; Matricon, P.; Eddy, M. T.; Carlsson, J. Adenosine A2A receptor antagonists: from caffeine to selective non-xanthines. Br. J. Pharmacol. 2020, DOI: 10.1111/bph.15103.
[20] Jacobson, K. A.; Gao, Z. G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug. Discov. 2006, 5, 247–264.
[21] Sek, K.; Molck, C.; Stewart, G. D.; Kats, L.; Darcy, P. K.; Beavis, P. A. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. Int. J. Mol. Sci. 2018, 19, 3837.
[22] Fredholm, B. B. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol. 1995, 76, 93–101.
[23] Eini, H.; Frishman, V.; Yulzari, R.; Kachko, L.; Lewis, E. C.; Chaimovitz, C.; Douvdevani, A. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor. Biochem. Pharmacol. 2015, 98, 110–118.
[24] Li, Y. F.; Ouyang, S. H.; Tu, L. F.; Wang, X.; Yuan, W. L.; Wang, G. E.; Wu, Y. P.; Duan, W. J.; Yu, H. M.; Fang, Z. Z.; Kurihara, H.; Zhang, Y.; He, R. R. Caffeine Protects Skin from Oxidative Stress-Induced Senescence through the Activation of Autophagy. Theranostics 2018, 8, 5713–5730.
[25] Spencer, N. Y.; Stanton, R. C. Glucose 6-phosphate dehydrogenase and the kidney. Curr. Opin. Nephrol. Hypertens. 2017, 26, 43–49.
[26] Wang, Y. P.; Zhou, L. S.; Zhao, Y. Z.; Wang, S. W.; Chen, L. L.; Liu, L. X.; Ling, Z. Q.; Hu, F. J.; Sun, Y. P.; Zhang, J. Y.; Yang, C.; Yang, Y.; Xiong, Y.; Guan, K. L.; Ye, D. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 2014, 33, 1304–1320.
[27] Zhang, C.; Zhang, Z.; Zhu, Y.; Qin, S. Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer. Anticancer Agents Med. Chem. 2014, 14, 280–289.
[28] Liberti, M. V.; Dai, Z.; Wardell, S. E.; Baccile, J. A.; Liu, X.; Gao, X.; Baldi, R.; Mehrmohamadi, M.; Johnson, M. O.; Madhukar, N. S.; Shestov, A. A.; Chio, I. I. C.; Elemento, O.; Rathmell, J. C.; Schroeder, F. C.; McDonnell, D. P.; Locasale, J. W. A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metab. 2017, 26, 648–659.
[29] Liou, G. Y.; Storz, P. Reactive oxygen species in cancer. Free Radic. Res. 2010, 44, 479–496.
[30] Waris, G.; Ahsan, H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog. 2006, 5, 14. [31] Sullivan, L. B.; Chandel, N. S. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2014, 2, 17.
[32] Lu, J.; Zhang, H.; Chen, X.; Zou, Y.; Li, J.; Wang, L.; Wu, M.; Zang, J.; Yu, Y.; Zhuang, W.; Xia, Q.; Wang, J. A small molecule activator of SIRT3 promotes deacetylation and activation of manganese superoxide dismutase. Free Radic. Biol. Med. 2017, 112, 287–297.

Recent Advances on Interaction Targets for Anticancer Activity of Caffeine

Recent Advances on Interaction Targets for Anticancer Activity of Caffeine

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	Lei Sun, Chuihao Kong, Huan Zhao, Deling Wu, Fengqing Xu. Progress in Terpenes from Genus Paeonia [J]. Medicine Research, 2021, 5(3-4): 210011-210011.
[2]	Carita Sallomy, Maija Lahtela-Kakkonen, and Juri M. Timonen. Recent Advances on Molecular Modeling Studies of Transient Receptor Potential Ankyrin 1[J]. Medicine Research, 2021, 5(1): 200021-200021.
[3]	Zhao Wang, Filipe Olim, Jingjing Sun, Ana Rute Neves, Fátima Mendes, Helena Tomás, and Ruilong Sheng. Prodrug Systems (II): A Perspective of Polymer-Based Doxorubicin Prodrug Systems towards Chemotherapy[J]. Medicine Research, 2021, 5(1): 200023-200023.
[4]	Xiu-Li Sun, Yin-Rong Xie, Ning Zhang, Cheng-Ting Zi, Xuan-Jun Wang, and Jun Sheng. Recent Advances on Small-Molecule Tubulin Inhibitors[J]. Medicine Research, 2021, 5(1): 200024-200024.
[5]	Zhonglie Yang, Li Lin, Xiaoyan Peng, Xinyi Yu, Xiaobin Zhang, Hezhong Jiang, and Jiahong Li. Adverse Reactions and Resistance of Anticancer Drug Cisplatin[J]. Medicine Research, 2021, 5(1): 200022-200022.
[6]	Hao Wang, Ji-Lei Liang, Qing-Ming He, Guo-Hai Zhou, Cun-Fu Li, Ping-He Wei, and Hao-Yan Dong. Flavonoids, Phenylethanoids and Phenylpropanoids from Rhodiola rosea L. and Their Lipid-Lowering Activities on Receptor 5-HT_2A[J]. Medicine Research, 2020, 4(4): 200018-200018.
[7]	. Contents: Med. Res. 4/2020 [J]. Medicine Research, 2020, 4(4): 0-0.
[8]	Jinyu Yi, Yingying Huang, and Chaoyan Zhang. Bletilla striata Polysaccharides: Structures and Functional Activities[J]. Medicine Research, 2020, 4(4): 200009-0.
[9]	Alessandra Campbell Pinheiro, Sarah Sant’Anna Maranhão, Guilherme Graziany Camelo Carvalho, Augusto César Aragão Oliveira, Cláudia Pessoa, Thaís Cristina Mendonça Nogueira, Cristiane França da Costa, Marcus Vinícius Nora de Souza. Synthesis and Cytotoxic Activity of Arenecarbaldehyde 2-Pyridinylhydrazone Derivatives[J]. Medicine Research, 2020, 4(4): 200016-200016.
[10]	Xiao-Jing Shen, Ting-Ting Zheng, Hong Wang, Jiao Cai, Cheng-Ting Zi, and Jiang-Ping Fan. Progress in Antitumor Activity of Diterpenoid Alkaloids[J]. Medicine Research, 2020, 4(4): 200015-200015.
[11]	Xiaodi Li, Rui Liu, Ping Wang, and Jun Zhu. An Effective Inhibitory of Triptolide on Ovarian Cancer[J]. Medicine Research, 2020, 4(4): 200017-200017.
[12]	Kuo Xu, Qian Liu, Lin Ni, Yong-Mei Du and Zhong-Feng Zhang. An Update on Chemical Constituents from Nicotiana tabacum L. and Their Bioactivities from 2017 to 2020[J]. Medicine Research, 2020, 4(4): 200019-200019.
[13]	Xiaojing Shena, Weiwei Jiang. Polysaccharides from Bletilla striata: Extraction, Optimization and Their Antioxidant Activities in vitro[J]. Medicine Research, 2020, 4(3): 200010-.
[14]	Bo-Ya Shi, Ze-Hao Wang, Xuan-Jun Wang Jun Sheng, and Cheng-Ting Zi. Recent Advances on Small-Molecule Epidermal Growth Factor Receptor Inhibitors[J]. Medicine Research, 2020, 4(3): 200011-.
[15]	Yingying Huang, Jinyu Yi, Chaoyan Zhang. Progress in Percutaneous Penetration Enhancers from Traditional Chinese Medicines[J]. Medicine Research, 2020, 4(3): 200008-.